UCB, a global biopharmaceutical company, announced that the European Commission (EC) has granted marketing authorization for Bimzelx (bimekizumab) for the treatment of active moderate to severe hidradenitis suppurativa (HS) in adults with an inadequate response to conventional systemic HS therapy
Roche announced data from the Phase III OCARINA II study (S31.006) of Ocrevus (ocrevuslizumab), an investigational twice-yearly, 10-minute subcutaneous (SC) injection
Voydeya (danicopan) has been approved in the European Union (EU) as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia